Please login to the form below
thyroid cancer
This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.
Merck KGaA to make $3m payout to patients after drug formulation complaints
According to lawyers working on behalf of the plaintiffs, the replacement caused patients to experience severe side effects, including hair loss, memory loss, weight gain and in some cases, thyroid cancer. ... Despite the company’s claims, French group
Latest news
-
Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
metastatic RET-mutant medullary thyroid cancer and advanced or metastatic RET fusion-positive thyroid cancer. ... Although RET activating fusions and mutations are only observed in a small number of cancer patients – around 1-2% in NSCLC and 10-20% in
-
Roche pays $775m upfront to access Blueprint’s RET programme
Administration (FDA) for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. ... Although RET activating fusions and mutations are only
-
Exelixis bounces back with new prostate cancer data
Exelixis previously attempted to tackle prostate cancer with cabozantinib back in 2014, but the drug was unable to show any survival benefit on its own. ... Cabozantinib, a c-MET and VEGFR2 inhibitor, is already approved under the brand name Cometriq as
-
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in phase 3 trials for non-small cell lung cancer and medullary thyroid cancer.
-
RET rivals Loxo and Blueprint face off with early-stage data
with BLU-667 for at least 24 weeks, and 49% across all patients with that type of cancer. ... Existing treatment of medullary and papillary thyroid cancer with multi-kinase inhibitors is limited by frequent dose modifications or interruptions due to
More from news
Approximately 9 fully matching, plus 53 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2016
Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal
-
EATRIS and the new age of partnering
In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker
-
Interview: AstraZeneca's Susan Galbraith
As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and
-
Pharma deals during August 2013
In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “holy
-
Eisai: Bucking the trend with R&D growth
III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
